$336.84
10.563.24%
À la fermeture: -
$336.84
N/A
Après les heures de négociation: 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Insulet Corp a un objectif de cours consensuel de $329.89 basé sur les évaluations de 29 analystes. Le plus élevé est $428, publié par Canaccord Genuity le novembre 7, 2025. Le plus bas est $184, publié par Leerink Partners le octobre 16, 2023. Les 3 évaluations d’analystes les plus récentes ont été publiées par Canaccord Genuity, RBC Capital et Wells Fargo le novembre 7, 2025, respectivement. Avec un objectif de cours moyen de $386 entre Canaccord Genuity, RBC Capital et Wells Fargo, il existe une variation implicite de 14.59% upside pour Insulet Corp selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Canaccord Genuity
RBC Capital
Wells Fargo
UBS
Truist Securities
1calculé à partir des notes des analystes
Notes d'analystes pour Insulet
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/07/2025 | 27.06% | Canaccord Genuity | $399 → $428 | Maintains | Buy | |||
11/07/2025 | 9.84% | RBC Capital | $365 → $370 | Maintains | Outperform | |||
11/07/2025 | 6.88% | Wells Fargo | $350 → $360 | Maintains | Overweight | |||
11/07/2025 | 5.39% | UBS | $320 → $355 | Maintains | Neutral | |||
11/07/2025 | 15.78% | Truist Securities | $365 → $390 | Reiterates | Buy → Buy | |||
11/07/2025 | -6.19% | Barclays | $301 → $316 | Maintains | Equal-Weight | |||
11/06/2025 | 18.75% | Jefferies | $375 → $400 | Maintains | Buy | |||
11/05/2025 | -10.64% | Barclays | $300 → $301 | Maintains | Equal-Weight | |||
10/21/2025 | 9.84% | Stifel | → $370 | Reinstates | → Buy | |||
09/29/2025 | 18.45% | Canaccord Genuity | $353 → $399 | Maintains | Buy | |||
09/08/2025 | 8.36% | Oppenheimer | $324 → $365 | Maintains | Outperform | |||
08/21/2025 | -10.94% | Barclays | $266 → $300 | Maintains | Equal-Weight | |||
08/08/2025 | 4.8% | Canaccord Genuity | $331 → $353 | Maintains | Buy | |||
08/08/2025 | 3.91% | RBC Capital | $330 → $350 | Maintains | Outperform | |||
08/08/2025 | 3.91% | Wells Fargo | $330 → $350 | Maintains | Overweight | |||
06/16/2025 | 8.36% | Truist Securities | → $365 | Initiates | → Buy | |||
05/30/2025 | 12.81% | Goldman Sachs | → $380 | Initiates | → Buy | |||
05/27/2025 | 6.88% | Raymond James | $328 → $360 | Maintains | Outperform | |||
05/22/2025 | 12.81% | Citigroup | $320 → $380 | Maintains | Buy | |||
05/13/2025 | 3.91% | Wolfe Research | → $350 | Upgrade | Peer Perform → Outperform | |||
05/09/2025 | -3.81% | Oppenheimer | $312 → $324 | Maintains | Outperform | |||
04/30/2025 | -21.03% | Barclays | $234 → $266 | Maintains | Equal-Weight | |||
04/29/2025 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
03/06/2025 | 0.94% | RBC Capital | → $340 | Initiates | → Outperform | |||
02/21/2025 | 5.39% | Citigroup | $310 → $355 | Maintains | Buy | |||
02/21/2025 | -2.62% | Raymond James | $294 → $328 | Reiterates | Outperform → Outperform | |||
02/21/2025 | -13.02% | Stifel | $245 → $293 | Maintains | Hold | |||
02/21/2025 | -7.97% | Piper Sandler | $285 → $310 | Maintains | Overweight | |||
02/21/2025 | -4.41% | Wells Fargo | $305 → $322 | Maintains | Overweight | |||
02/21/2025 | -3.81% | Canaccord Genuity | $304 → $324 | Maintains | Buy | |||
01/03/2025 | -3.81% | TD Cowen | $264 → $324 | Maintains | Buy | |||
12/12/2024 | -2.03% | JP Morgan | $280 → $330 | Maintains | Overweight | |||
12/11/2024 | -7.97% | Citigroup | $283 → $310 | Maintains | Buy | |||
12/11/2024 | -9.45% | Wells Fargo | $290 → $305 | Maintains | Overweight | |||
12/09/2024 | -9.75% | Canaccord Genuity | $269 → $304 | Maintains | Buy | |||
11/11/2024 | -30.53% | Barclays | $220 → $234 | Maintains | Equal-Weight | |||
11/11/2024 | -5.89% | Morgan Stanley | $234 → $317 | Maintains | Overweight | |||
11/08/2024 | -15.98% | Citigroup | $275 → $283 | Maintains | Buy | |||
11/08/2024 | -27.27% | Stifel | $185 → $245 | Maintains | Hold | |||
11/08/2024 | -19.84% | BTIG | $260 → $270 | Maintains | Buy | |||
11/06/2024 | -10.94% | Bernstein | → $300 | Initiates | → Outperform | |||
10/14/2024 | -22.81% | Raymond James | $213 → $260 | Maintains | Outperform | |||
10/14/2024 | -22.81% | BTIG | $250 → $260 | Maintains | Buy | |||
10/01/2024 | -18.36% | Citigroup | $250 → $275 | Maintains | Buy | |||
09/25/2024 | -20.14% | Canaccord Genuity | $236 → $269 | Maintains | Buy | |||
09/17/2024 | -15.39% | Piper Sandler | $230 → $285 | Maintains | Overweight | |||
08/12/2024 | -34.69% | Barclays | $200 → $220 | Maintains | Equal-Weight | |||
08/09/2024 | -25.78% | BTIG | $270 → $250 | Maintains | Buy | |||
08/09/2024 | -33.8% | UBS | $211 → $223 | Maintains | Neutral | |||
07/23/2024 | -30.53% | Canaccord Genuity | $234 → $234 | Maintains | Buy | |||
06/10/2024 | — | OTR Global | — | — | Downgrade | Positive → Mixed | ||
05/30/2024 | -30.23% | Redburn Atlantic | → $235 | Initiates | → Buy | |||
05/13/2024 | -40.62% | Barclays | $213 → $200 | Maintains | Equal-Weight | |||
05/10/2024 | -45.08% | Stifel | $208 → $185 | Maintains | Hold | |||
05/10/2024 | -30.53% | Canaccord Genuity | $226 → $234 | Maintains | Buy | |||
05/10/2024 | -36.77% | Raymond James | $218 → $213 | Maintains | Outperform | |||
05/10/2024 | -22.81% | Jefferies | $255 → $260 | Maintains | Buy | |||
05/07/2024 | -40.62% | Wolfe Research | → $200 | Upgrade | Peer Perform → Outperform | |||
02/26/2024 | -36.77% | Barclays | $214 → $213 | Maintains | Equal-Weight | |||
02/23/2024 | -31.72% | Piper Sandler | $250 → $230 | Maintains | Overweight | |||
02/23/2024 | -33.2% | JP Morgan | $190 → $225 | Maintains | Overweight | |||
02/05/2024 | -38.25% | Stifel | $163 → $208 | Maintains | Hold | |||
12/21/2023 | -29.34% | Baird | $180 → $238 | Upgrade | Neutral → Outperform | |||
12/04/2023 | -30.53% | Morgan Stanley | $185 → $234 | Upgrade | Equal-Weight → Overweight | |||
11/03/2023 | -25.78% | Piper Sandler | $325 → $250 | Maintains | Overweight | |||
10/17/2023 | -51.91% | JP Morgan | $325 → $162 | Maintains | Overweight | |||
10/16/2023 | -45.37% | Leerink Partners | → $184 | Initiates | → Outperform | |||
10/02/2023 | -28.75% | Jefferies | $260 → $240 | Upgrade | Hold → Buy | |||
09/29/2023 | -45.08% | Morgan Stanley | $208 → $185 | Maintains | Equal-Weight | |||
09/15/2023 | -32.31% | Raymond James | $299 → $228 | Maintains | Outperform | |||
09/06/2023 | -36.17% | UBS | $270 → $215 | Maintains | Neutral | |||
08/24/2023 | -12.42% | B of A Securities | $365 → $295 | Maintains | Buy | |||
08/24/2023 | -38.25% | Morgan Stanley | $343 → $208 | Maintains | Equal-Weight | |||
08/21/2023 | -21.33% | Citigroup | $273 → $265 | Upgrade | Neutral → Buy | |||
08/21/2023 | -34.98% | Baird | $320 → $219 | Downgrade | Outperform → Neutral | |||
08/10/2023 | -23.7% | Barclays | $329 → $257 | Maintains | Equal-Weight | |||
08/09/2023 | -10.94% | TD Cowen | $350 → $300 | Maintains | Outperform | |||
08/09/2023 | -3.52% | JP Morgan | $365 → $325 | Maintains | Overweight | |||
08/09/2023 | -18.95% | Citigroup | $319 → $273 | Maintains | Neutral | |||
08/09/2023 | -2.03% | Wells Fargo | $375 → $330 | Maintains | Overweight | |||
08/09/2023 | -11.23% | Raymond James | $350 → $299 | Maintains | Outperform | |||
07/11/2023 | -5.3% | Citigroup | $330 → $319 | Maintains | Neutral | |||
05/30/2023 | 1.83% | Morgan Stanley | → $343 | Assumes | → Equal-Weight | |||
05/08/2023 | -2.33% | Barclays | $292 → $329 | Maintains | Equal-Weight | |||
05/05/2023 | 1.83% | Morgan Stanley | $325 → $343 | Maintains | Equal-Weight | |||
05/05/2023 | 3.91% | Raymond James | $334 → $350 | Maintains | Outperform | |||
05/05/2023 | 6.88% | Piper Sandler | $340 → $360 | Maintains | Overweight | |||
05/05/2023 | 9.84% | Baird | $350 → $370 | Maintains | Outperform | |||
04/20/2023 | 1.53% | Stifel | $300 → $342 | Maintains | Hold | |||
04/17/2023 | 3.91% | BTIG | $340 → $350 | Maintains | Buy | |||
02/24/2023 | -0.84% | Raymond James | $320 → $334 | Maintains | Outperform | |||
02/24/2023 | -3.52% | Morgan Stanley | $320 → $325 | Maintains | Equal-Weight | |||
02/24/2023 | 3.91% | Baird | $340 → $350 | Maintains | Outperform | |||
01/26/2023 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
01/06/2023 | -5% | Morgan Stanley | $300 → $320 | Maintains | Equal-Weight |
FAQ
Quel est le cours indicatif de l'action Insulet (PODD) ?
Le dernier objectif de prix pour Insulet (NASDAQ:PODD) a été rapporté par Canaccord Genuity le novembre 7, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $428.00 s'attendant à ce que PODD se rise dans les 12 prochains mois (un possible changement de 27.06% upside). 35 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Insulet (PODD) ?
La dernière note d'analyste pour Insulet (NASDAQ:PODD) a été fournie par Canaccord Genuity, et Insulet maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Insulet (PODD) ?
La dernière amélioration pour Insulet Corp a eu lieu le mai 13, 2025 lorsque Wolfe Research a augmenté leur objectif de prix à $350. Wolfe Research avait précédemment a peer perform pour Insulet Corp.
Quand a eu lieu la dernière dégradation pour Insulet (PODD) ?
La dernière réduction pour Insulet Corp a eu lieu le avril 29, 2025 lorsque Wolfe Research a changé leur objectif de prix de N/A à N/A pour Insulet Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Insulet (PODD) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Insulet, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Insulet a été déposée le novembre 7, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 7, 2026.
La note d'analyste pour Insulet (PODD) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Insulet (PODD) était un maintenu avec un objectif de prix de $399.00 à $428.00. Le prix actuel de Insulet (PODD) est de $336.84, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.